Physician profile
Arvind Kumar
NPI 1861590689
$6,648.20
in general payments reported to CMS, 2019-2025
68 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $728 · 2021: $606 · 2022: $491 · 2023: $2,323 · 2024: $2,241 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,717.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $681.77 | 2020-2025 | Kisqali, Piqray |
| Daiichi Sankyo INC. | $650.92 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $342.90 | 2019-2024 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $335.41 | 2020-2025 | Enhertu, Lynparza, Calquence |
| Pfizer INC. | $286.54 | 2022-2024 | |
| Abbvie INC. | $266.67 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $235.82 | 2023-2024 | Libtayo |
| Lilly USA, LLC | $222.18 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $187.20 | 2020-2024 | Opdivo, Opdualag |
| Eisai INC. | $183.11 | 2020-2024 | |
| Genentech USA, INC. | $179.13 | 2021-2024 | Tecentriq, Venclexta, Avastin |
| Takeda Pharmaceuticals U.S.A., INC. | $176.97 | 2023-2024 | Ninlaro, Alunbrig, Fruzaqla |
| Astellas Pharma US INC | $168.51 | 2022-2025 | Xtandi, Padcev, Xospata |
| Incyte Corporation | $159.54 | 2021-2025 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $157.54 | 2021-2024 | Erleada, Carvykti, Balversa |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.